Eric Wexler, M.D., Ph.D., Modern Brains PsychiatryEric Wexler, M.D., Ph.D.Diplomate, American Board of Psychiatry & Neurology

Special Topics

References and Citations

Every source cited across the special topics articles on this site, grouped by topic. 331 citations in total.

MAOIs in Depression

Read the article →
  1. Bai, A. D., McKenna, S., Wise, H., Loeb, M., & Gill, S. S. (2022). Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Network Open, 5(12), e2247426. https://doi.org/10.1001/jamanetworkopen.2022.47426
  2. Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Molecular Psychiatry, 24(2), 198-217. https://doi.org/10.1038/s41380-018-0044-2
  3. Berlin, I., Zimmer, R., Cournot, A., et al. (1989). Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clinical Pharmacology and Therapeutics, 46(3), 344-51. https://doi.org/10.1038/clpt.1989.149
  4. Bieck, P. R., Firkusny, L., Schick, C., et al. (1989). Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clinical Pharmacology and Therapeutics, 45(3), 260-9. https://doi.org/10.1038/clpt.1989.26
  5. Birkenhager, T. K., & Heijnen, W. T. (2024). Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression. Acta Psychiatrica Scandinavica, 150(6), 497-499. https://doi.org/10.1111/acps.13753
  6. Brockington, R., Buelt, A., Capaldi, V., et al. (2022). Management of Major Depressive Disorder (MDD). Department of Veterans Affairs.
  7. Browne, B., & Linter, S. (1987). Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. The British Journal of Psychiatry, 151, 210-2. https://doi.org/10.1192/bjp.151.2.210
  8. Citrome, L., Goldberg, J. F., & Portland, K. B. (2013). Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 151(2), 409-417. https://doi.org/10.1016/j.jad.2013.06.027
  9. Elli, C., Novella, A., & Pasina, L. (2024). Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levels. European Journal of Clinical Pharmacology, 80(2), 231-237. https://doi.org/10.1007/s00228-023-03596-z
  10. Food and Drug Administration. (2020). EMSAM. Updated date: 2020-05-15.
  11. Food and Drug Administration. (2024). Fluoxetine. Updated date: 2024-12-11.
  12. Food and Drug Administration. (2025). Tranylcypromine Sulfate. Updated date: 2025-07-25.
  13. Food and Drug Administration. (2026). Phenelzine sulfate. Updated date: 2026-05-21.
  14. Fornaro, M., Caiazza, C., Pistone, L., et al. (2025). Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 96, 46-57. https://doi.org/10.1016/j.euroneuro.2025.04.003
  15. Fulton, B., & Benfield, P. (1996). Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs, 52(3), 450-74. https://doi.org/10.2165/00003495-199652030-00013
  16. Gardner, D. M., Shulman, K. I., Walker, S. E., & Tailor, S. A. (1996). The making of a user friendly MAOI diet. The Journal of Clinical Psychiatry, 57(3), 99-104.
  17. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-41. https://doi.org/10.1093/bja/aei210
  18. Giménez-Palomo, A., Chamdal, A. K., Gottlieb, N., et al. (2024). Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysis. Acta Psychiatrica Scandinavica, 150(6), 500-515. https://doi.org/10.1111/acps.13728
  19. Heijnen, W. T., De Fruyt, J., Wierdsma, A. I., Sienaert, P., & Birkenhäger, T. K. (2015). Efficacy of tranylcypromine in bipolar depression: A systematic review. Journal of Clinical Psychopharmacology, 35(6), 700-5. https://doi.org/10.1097/JCP.0000000000000409
  20. Himmelhoch, J. M., Thase, M. E., Mallinger, A. G., & Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. The American Journal of Psychiatry, 148(7), 910-6. https://doi.org/10.1176/ajp.148.7.910
  21. Jeste, D. V., Lieberman, J. A., Fassler, D., et al. (2022). Diagnostic and statistical manual of mental disorders. American Psychiatric Association.
  22. Kim, T. T., & Amsterdam, J. D. (2023). Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study. Acta Psychiatrica Scandinavica, 147(2), 198-204. https://doi.org/10.1111/acps.13518
  23. Lotufo-Neto, F., Trivedi, M., & Thase, M. E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type a moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology, 20(3), 226-47. https://doi.org/10.1016/S0893-133X(98)00075-X
  24. Lu, Y., Chen, J., Fan, N., et al. (2026). Machine learning models for drug-drug interaction prediction from computational discovery to clinical application. NPJ Digital Medicine, 9(1), 198. https://doi.org/10.1038/s41746-026-02400-3
  25. Mann, J. J. (2005). The medical management of depression. The New England Journal of Medicine, 353(17), 1819-34. https://doi.org/10.1056/NEJMra050730
  26. Nihalani, N., Schwartz, T. L., Siddiqui, U. A., & Megna, J. L. (2012). Obesity and psychotropics. CNS Neuroscience & Therapeutics, 18(1), 57-63. https://doi.org/10.1111/j.1755-5949.2011.00232.x
  27. Norman, T. R., & Burrows, G. D. (1995). A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Safety, 12(1), 46-54. https://doi.org/10.2165/00002018-199512010-00004
  28. Parker, G. B., Graham, R. K., & Tavella, G. (2017). Is there consensus across international evidence-based guidelines for the management of bipolar disorder?. Acta Psychiatrica Scandinavica, 135(6), 515-526. https://doi.org/10.1111/acps.12717
  29. Potter, W. Z., Rudorfer, M. V., & Manji, H. (1991). The pharmacologic treatment of depression. The New England Journal of Medicine, 325(9), 633-42. https://doi.org/10.1056/NEJM199108293250907
  30. Remick, R. A., Froese, C., & Keller, F. D. (1989). Common side effects associated with monoamine oxidase inhibitors. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(3-4), 497-504. https://doi.org/10.1016/0278-5846(89)90137-1
  31. Shulman, K. I., & Walker, S. E. (1999). Refining the MAOI diet: Tyramine content of pizzas and soy products. The Journal of Clinical Psychiatry, 60(3), 191-3.
  32. Suchting, R., Tirumalajaru, V., Gareeb, R., et al. (2021). Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. Journal of Affective Disorders, 282, 1153-1160. https://doi.org/10.1016/j.jad.2021.01.021
  33. Thase, M. E. (2012). MAOIs and depression treatment guidelines. The Journal of Clinical Psychiatry, 73(7), e24. https://doi.org/10.4088/JCP.11096tx4c
  34. Truman, C. J., Goldberg, J. F., Ghaemi, S. N., et al. (2007). Self-reported history of manic/hypomanic switch associated with antidepressant use: Data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). The Journal of Clinical Psychiatry, 68(10), 1472-9. https://doi.org/10.4088/jcp.v68n1002
  35. Ulrich, S., Ricken, R., Buspavanich, P., Schlattmann, P., & Adli, M. (2020). Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: A systematic review and comprehensive meta-analysis. Journal of Clinical Psychopharmacology, 40(1), 63-74. https://doi.org/10.1097/JCP.0000000000001153
  36. Van den Eynde, V., Abdelmoemin, W. R., Abraham, M. M., et al. (2023). The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectrums, 28(4), 427-440. https://doi.org/10.1017/S1092852922000906
  37. Van den Eynde, V., Gillman, P. K., & Blackwell, B. B. (2022). The prescriber's guide to the MAOI diet-thinking through tyramine troubles. Psychopharmacology Bulletin, 52(2), 73-116.
  38. Volz, H. P., & Gleiter, C. H. (1998). Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs & Aging, 13(5), 341-55. https://doi.org/10.2165/00002512-199813050-00002
  39. Walker, S. E., Shulman, K. I., Tailor, S. A., & Gardner, D. (1996). Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. Journal of Clinical Psychopharmacology, 16(5), 383-8. https://doi.org/10.1097/00004714-199610000-00007
  40. Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
  41. Youdim, M. B., & Riederer, P. F. (2004). A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology, 63(7 Suppl 2), S32-5. https://doi.org/10.1212/wnl.63.7_suppl_2.s32

Neuroleptic Malignant Syndrome

Read the article →
  1. Bai, A. D., McKenna, S., Wise, H., Loeb, M., & Gill, S. S. (2022). Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Network Open, 5(12), e2247426.
  2. Berardi, D., Amore, M., Keck, P. E., Troia, M., & Dell'Atti, M. (1998). Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study. Biological Psychiatry, 44(8), 748-754.
  3. Blyzniuk, B., Danukalo, M., Gastaldon, C., et al. (2026). Precipitants and clinical features of serotonin syndrome: A systematic review with patient-level analysis of published case reports and series. European Journal of Clinical Pharmacology, 82(8), 210.
  4. Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. The New England Journal of Medicine, 352(11), 1112-1120.
  5. Chen, A., & Bae, M. (2025). Lorazepam in managing atypical neuroleptic malignant syndrome: A systematic review of case reports. The Western Journal of Emergency Medicine, 26(5), 1446-1453.
  6. Chun, T. H., Mace, S. E., Katz, E. R., et al. (2016). Evaluation and management of children with acute mental health or behavioral problems. Part II: Recognition of clinically challenging mental health related conditions presenting with medical or uncertain symptoms. Pediatrics, 138(3), e20161573.
  7. Dos Santos, D. T., Imthon, A. K., Strelow, M. Z., Pille, A., & Schumacher-Schuh, A. F. (2021). Parkinsonism-hyperpyrexia syndrome after amantadine withdrawal: Case report and review of the literature. The Neurologist, 26(4), 149-152.
  8. Dunkley, E. J., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003). The Hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM, 96(9), 635-642.
  9. Evans, R. W., Tepper, S. J., Shapiro, R. E., Sun-Edelstein, C., & Tietjen, G. E. (2010). The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache, 50(6), 1089-1099.
  10. Factor, S. A., Burkhard, P. R., Caroff, S., et al. (2019). Recent developments in drug-induced movement disorders: A mixed picture. The Lancet Neurology, 18(9), 880-890.
  11. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  12. Guinart, D., Misawa, F., Rubio, J. M., et al. (2021). A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 144(4), 329-341.
  13. Gurrera, R. J., Caroff, S. N., Cohen, A., et al. (2011). An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. The Journal of Clinical Psychiatry, 72(9), 1222-1228.
  14. Gurrera, R. J., Gearin, P. F., Love, J., et al. (2022). Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis. Acta Psychiatrica Scandinavica, 145(5), 423-441.
  15. He, J., Luo, X., Li, C., et al. (2025). Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA Adverse Event Reporting System Database. Journal of Affective Disorders, 386, 119481.
  16. Hocker, S., Kenney, D. L., & Ramar, K. (2013). Parkinsonism-hyperpyrexia syndrome: Broadening our differential diagnosis in the ICU. Neurology Clinical Practice, 3(6), 535-538.
  17. Isik, A. T., Kaya, D., Ontan, M. S., et al. (2023). Neuroleptic malignant syndrome in patients with dementia: Experiences of a single memory clinic. Clinical Neuropharmacology, 46(6), 209-213.
  18. Jeste, D. V., Lieberman, J. A., Fassler, D., et al. (2022). Diagnostic and statistical manual of mental disorders. American Psychiatric Association.
  19. Jurawan, K. T., & Eachnie, N. M. (2026). EP16.184: Atypical neuroleptic malignant syndrome in early pregnancy. Ultrasound in Obstetrics & Gynecology, 68(Suppl 1), 415-416.
  20. Karagianis, J. L., Phillips, L. C., Hogan, K. P., & LeDrew, K. K. (1999). Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. The Annals of Pharmacotherapy, 33(5), 623-630.
  21. Kato, D., Kawanishi, C., Kishida, I., et al. (2007). Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. European Journal of Clinical Pharmacology, 63(11), 991-996.
  22. Kawai, Y., DeMonbrun, A. G., Chambers, R. S., et al. (2017). A previously healthy adolescent with acute encephalopathy and decorticate posturing. Pediatrics, 139(1), e20153779.
  23. King, E., & Rotella, J. A. (2025). Review article: Efficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning: a systematic review. Emergency Medicine Australasia, 37(1), e14554.
  24. Kishida, I., Kawanishi, C., Furuno, T., et al. (2004). Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Molecular Psychiatry, 9(3), 293-298.
  25. Kuhlwilm, L., Schönfeldt-Lecuona, C., Gahr, M., et al. (2020). The neuroleptic malignant syndrome: a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatrica Scandinavica, 142(3), 233-241.
  26. Lally, J., McCaffrey, C., O'Murchu, C., et al. (2019). Clozapine rechallenge following neuroleptic malignant syndrome: A systematic review. Journal of Clinical Psychopharmacology, 39(4), 372-379.
  27. Le Quang, M., Solé, G., Martin-Négrier, M. L., & Mathis, S. (2024). Clinical and pathological aspects of toxic myopathies. Journal of Neurology, 271(9), 5722-5745.
  28. Mizumura, N., Uematsu, M., Ito, A., et al. (2017). "Brief" aripiprazole-induced neuroleptic malignant syndrome with symptoms that only lasted a few hours. Internal Medicine, 56(22), 3089-3092.
  29. Newman, E. J., Grosset, D. G., & Kennedy, P. G. (2009). The parkinsonism-hyperpyrexia syndrome. Neurocritical Care, 10(1), 136-140.
  30. Nguyen, H., Pan, A., Smollin, C., Cantrell, L. F., & Kearney, T. (2019). An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. Journal of Clinical Pharmacy and Therapeutics, 44(2), 327-334.
  31. Oruch, R., Pryme, I. F., Engelsen, B. A., & Lund, A. (2017). Neuroleptic malignant syndrome: An easily overlooked neurologic emergency. Neuropsychiatric Disease and Treatment, 13, 161-175.
  32. Pande, C. K., O'Halloran, A., Stewart, R. W., Nguyen, A., & Canares, T. (2019). Case 2: Agitation and abnormal movements in a 14-year-old boy. Pediatrics in Review, 40(10), 532-534.
  33. Perry, P. J., & Wilborn, C. A. (2012). Serotonin syndrome vs neuroleptic malignant syndrome: A contrast of causes, diagnoses, and management. Annals of Clinical Psychiatry, 24(2), 155-162.
  34. Picard, L. S., Lindsay, S., Strawn, J. R., et al. (2008). Atypical neuroleptic malignant syndrome: Diagnostic controversies and considerations. Pharmacotherapy, 28(4), 530-535.
  35. Pötter-Nerger, M., Löhle, M., Höglinger, G., & German Parkinson's Guideline Group. (2024). Akinetic crisis and withdrawal syndromes: Guideline "Parkinson's disease" of the German Society of Neurology. Journal of Neurology, 271(10), 6485-6493.
  36. Robottom, B. J., Weiner, W. J., & Factor, S. A. (2011). Movement disorders emergencies part 1: Hypokinetic disorders. Archives of Neurology, 68(5), 567-572.
  37. Sachdev, P., Kruk, J., Kneebone, M., & Kissane, D. (1995). Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. Journal of Clinical Psychopharmacology, 15(5), 365-371.
  38. Schneider, M., Regente, J., Greiner, T., et al. (2020). Neuroleptic malignant syndrome: Evaluation of drug safety data from the AMSP program during 1993–2015. European Archives of Psychiatry and Clinical Neuroscience, 270(1), 23-33.
  39. Schönfeldt-Lecuona, C., Kuhlwilm, L., Cronemeyer, M., et al. (2020). Treatment of the neuroleptic malignant syndrome in international therapy guidelines: A comparative analysis. Pharmacopsychiatry, 53(2), 51-59.
  40. Scott, F. A. M., Butler, M., & Rogers, J. P. (2024). The limited clinical utility of a routine creatine kinase (CK) on admission to a psychiatric inpatient unit. BMC Psychiatry, 24(1), 908.
  41. Shin, M. H., Jeong, J. W., & Yu, T. Y. (2025). Concurrence of clozapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome: A case report. Medicine, 104(34), e44172.
  42. Su, Y. P., Chang, C. K., Hayes, R. D., et al. (2014). Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 130(1), 52-60.
  43. Suekane, A., Senda, A., Morishita, K., & Fushimi, K. (2026). Clinical outcomes of dantrolene in neuroleptic malignant syndrome: A nationwide retrospective study. Acta Psychiatrica Scandinavica, 153(6), 627-635.
  44. Susman, V. L., & Addonizio, G. (1988). Recurrence of neuroleptic malignant syndrome. The Journal of Nervous and Mental Disease, 176(4), 234-241.
  45. Suzuki, A., Kondo, T., Otani, K., et al. (2001). Association of the TaqI a polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. The American Journal of Psychiatry, 158(10), 1714-1716.
  46. Szota, A. M., Radajewska, I., & Araszkiewicz, A. S. (2022). Atypical neuroleptic malignant syndrome: Case reports and diagnostic challenges. Journal of Psychoactive Drugs, 54(3), 284-293.
  47. Tee, Z. J. (2024). Prochlorperazine-induced neuroleptic malignant syndrome. The American Journal of Emergency Medicine, 81, 160.e1-160.e2.
  48. Trollor, J. N., Chen, X., Chitty, K., & Sachdev, P. S. (2012). Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. The British Journal of Psychiatry, 201(1), 52-56.
  49. Wijdicks, E. F. M., & Ropper, A. H. (2024). Neuroleptic malignant syndrome. The New England Journal of Medicine, 391(12), 1130-1138.
  50. Wilson, J. E., Oldham, M. A., Francis, A., et al. (2025). Resource document on catatonia. American Psychiatric Association.
  51. Wittmann, O., Sadot, E., Bisker-Kassif, O., et al. (2016). Neuroleptic malignant syndrome associated with metoclopramide use in a boy: Case report and review of the literature. American Journal of Therapeutics, 23(5), e1246-1249.

rTMS in Schizophrenia

Read the article →
  1. Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis. Kishi T, Ikuta T, Sakuma K, et al. JAMA Network Open. 2024;7(10):e2441159. doi:10.1001/jamanetworkopen.2024.41159.
  2. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. McClintock SM, Reti IM, Carpenter LL, et al. The Journal of Clinical Psychiatry. 2018;79(1):16cs10905. doi:10.4088/JCP.16cs10905.
  3. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Wada M, Noda Y, Iwata Y, et al. Molecular Psychiatry. 2022;27(7):2950-2967. doi:10.1038/s41380-022-01572-0.
  4. Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia. Tseng PT, Zeng BS, Hung CM, et al. JAMA Psychiatry. 2022;79(8):770-779. doi:10.1001/jamapsychiatry.2022.1513.
  5. Andreasen NC, Paradiso S, O'Leary DS. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophrenia Bulletin. 1998;24(2):203-218.
  6. Hoffman RE, Hawkins KA, Gueorguieva R, et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Archives of General Psychiatry. 2003;60(1):49-56.
  7. Transcriptomic and Neurotransmitter Insights Into Gray Matter Volume Changes From 1 Hz rTMS in Treating Schizophrenia With Auditory Verbal Hallucinations. Xie Y, Li C, Guan M, et al. Acta Psychiatrica Scandinavica. 2025;152(5):372-392. doi:10.1111/acps.70014.
  8. Review of the Efficacy of Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations. Slotema CW, Blom JD, van Lutterveld R, Hoek HW, Sommer IE. Biological Psychiatry. 2014;76(2):101-110. doi:10.1016/j.biopsych.2013.09.038.
  9. He H, Yang M, Duan M, et al. Efficacy of repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: a meta-analysis. Psychiatry Research. 2020;290:113141.
  10. Li W, et al. Repetitive transcranial magnetic stimulation for auditory verbal hallucinations in schizophrenia: systematic review and meta-analysis. 2020.
  11. Guttesen KV, et al. Repetitive transcranial magnetic stimulation for auditory hallucinations in schizophrenia. 2021.
  12. Dollfus S, et al. Negative and sham-controlled trials of rTMS in schizophrenia. 2018.
  13. Network meta-analysis of neuromodulation for treatment-resistant schizophrenia. 2026.
  14. Pairwise meta-analysis of low-frequency rTMS for auditory hallucinations in treatment-resistant schizophrenia. 2026.
  15. Geographic bias in rTMS-for-schizophrenia trials: sensitivity analyses excluding mainland-China studies. 2022.
  16. Hua L, et al. Imaging-navigated low-frequency rTMS for auditory verbal hallucinations in schizophrenia: a randomized clinical trial. JAMA Network Open. 2024.
  17. Bais L, Vercammen A, Stewart R, et al. Short and long term effects of left and bilateral repetitive transcranial magnetic stimulation in schizophrenia patients with auditory verbal hallucinations: a randomized controlled trial. PLoS ONE. 2014;9(10):e108828.
  18. Koops S, et al. Continuous theta burst stimulation for refractory auditory verbal hallucinations in schizophrenia. Schizophrenia Research. 2016.
  19. Lv Q, et al. Low-frequency rTMS for auditory hallucinations: a sham-controlled trial. 2025.
  20. Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation Across Mental Disorders: A Systematic Review and Dose-Response Meta-Analysis. Sabé M, Hyde J, Cramer C, et al. JAMA Network Open. 2024;7(5):e2412616. doi:10.1001/jamanetworkopen.2024.12616.
  21. Theta Burst Stimulation of Temporo-Parietal Cortex Regions for the Treatment of Persistent Auditory Hallucinations: A Multicentre, Randomised, Sham-Controlled, Triple-Blind Phase 3 Trial in Germany. Plewnia C, Brendel B, Schwippel T, et al. The Lancet Psychiatry. 2025;12(9):638-649. doi:10.1016/S2215-0366(25)00202-0.
  22. Slotema CW, Blom JD, de Weijer AD, et al. Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry. 2011;69(5):450-456.
  23. Wang Y, et al. High-frequency rTMS for negative symptoms of schizophrenia measured by PANSS: a meta-analysis. 2024.
  24. Chen J, et al. High-frequency rTMS for negative symptoms in schizophrenia: systematic review and meta-analysis. 2025.
  25. Lorentzen R, et al. Transcranial magnetic stimulation for the treatment of schizophrenia: a systematic review and meta-analysis. 2022.
  26. Aleman A, et al. Efficacy of non-invasive brain stimulation for negative symptoms in schizophrenia: meta-analysis. 2018.
  27. Osoegawa C, et al. Meta-analysis of the effects of rTMS on negative symptoms in schizophrenia. 2018.
  28. Wobrock T, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial (RESIS). Biological Psychiatry. 2015.
  29. Brain stimulation effects and thresholds for clinically meaningful improvement: a meta-analysis of 451 RCTs. 2026.
  30. Double-blind trial of left-DLPFC iTBS for negative symptoms in schizophrenia (N=141). 2026.
  31. Aleman A, et al. Non-invasive brain stimulation for cognitive symptoms in schizophrenia. 2018.
  32. Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) on Negative Symptoms and Cognitive Functioning in Schizophrenia: An Umbrella Review of Systematic Reviews and Meta-Analyses. Yi S, Wang Q, Wang W, Hong C, Ren Z. Psychiatry Research. 2024;333:115728. doi:10.1016/j.psychres.2024.115728.
  33. Delayed cognitive benefits of rTMS at 6-month follow-up in schizophrenia. 2021.
  34. Long-term follow-up of rTMS cognitive effects in schizophrenia. 2022.
  35. Accelerated iTBS to the left DLPFC and social cognition in schizophrenia. 2023.
  36. Low-frequency rTMS over the supplementary motor area for psychomotor slowing in schizophrenia: a randomized controlled trial. JAMA Psychiatry. 2023.
  37. Brady RO Jr, et al. Cerebellar-prefrontal network connectivity and negative symptoms in schizophrenia. American Journal of Psychiatry. 2019.
  38. Cerebellar vermal iTBS for negative symptoms in schizophrenia: randomized controlled trials. 2020-2024.
  39. Normalization of cerebellar Glx/GABA ratio after cerebellar TBS in schizophrenia. 2023.
  40. Negative cerebellar stimulation trial attributed to under-dosing. 2024.
  41. One-hertz right orbitofrontal rTMS in first-episode schizophrenia. 2021.
  42. Visuospatial memory improvement with right-OFC rTMS in first-episode schizophrenia. 2022.
  43. Dorsomedial prefrontal stimulation for negative and cognitive symptoms in schizophrenia. 2022.
  44. Superior frontal gyrus targeting for negative symptoms in schizophrenia. 2023.
  45. Intermittent Theta Burst Stimulation for Negative Symptoms in Schizophrenia Patients With Moderate to Severe Cognitive Impairment: A Randomized Controlled Trial. Li J, Jiang D, Huang X, et al. Psychiatry and Clinical Neurosciences. 2025;79(4):147-157. doi:10.1111/pcn.13779.
  46. MRI-guided neuronavigation and stimulation-to-target deviation in rTMS for schizophrenia. 2023.
  47. Functional-connectivity-based and alpha-peak-frequency-guided TMS targeting. 2024.
  48. Combination of rTMS with working-memory training in schizophrenia. 2022.
  49. Combination of rTMS with cognitive behavioral therapy in schizophrenia. 2023.
  50. Safety of rTMS in schizophrenia: a meta-analysis of 126 studies (N=4,122). 2021.
  51. Rossi S, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology. 2009/2021.
  52. Dropout rates with rTMS versus sham in schizophrenia trials. 2022.
  53. Clozapine and seizure risk: dose-dependent incidence. 2020.
  54. Comparative seizure risk among antipsychotics. 2021.
  55. VA/DoD Clinical Practice Guideline for the Management of Schizophrenia. 2023.
  56. Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology. 2020.
  57. Schizophrenia. Leucht S, Siafis S, McGrath JJ, et al. Nature Reviews Disease Primers. 2025;11(1):83. doi:10.1038/s41572-025-00667-6.
  58. Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms: study protocol for a double-blind, sham-controlled, randomized clinical trial. Csukly G, Orbán-Szigeti B, Suri K, et al. Trials. 2024;25(1):269. doi:10.1186/s13063-024-08106-9.

Postpartum Psychosis

Read the article →
  1. Abu-Zaid, A., Gari, A., Alsharif, S. A., et al. (2023). Exploring the impact of chronic medical conditions on maternal mental health: A national inpatient sample analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 289, 42-47. https://doi.org/10.1016/j.ejogrb.2023.08.011
  2. Alford, A. Y., Riggins, A. D., Chopak-Foss, J., et al. (2025). A systematic review of postpartum psychosis resulting in infanticide: Missed opportunities in screening, diagnosis, and treatment. Archives of Women's Mental Health, 28(2), 297-308. https://doi.org/10.1007/s00737-024-01508-3
  3. Appleby, L., Mortensen, P. B., & Faragher, E. B. (1998). Suicide and other causes of mortality after post-partum psychiatric admission. The British Journal of Psychiatry, 173, 209-211. https://doi.org/10.1192/bjp.173.3.209
  4. Babu, G. N., Subbakrishna, D. K., & Chandra, P. S. (2008). Prevalence and correlates of suicidality among Indian women with post-partum psychosis in an inpatient setting. Australian and New Zealand Journal of Psychiatry, 42(11), 976-980. https://doi.org/10.1080/00048670802415384
  5. Babu, G. N., Thippeswamy, H., & Chandra, P. S. (2013). Use of electroconvulsive therapy (ECT) in postpartum psychosis, a naturalistic prospective study. Archives of Women's Mental Health, 16(3), 247-251. https://doi.org/10.1007/s00737-013-0342-2
  6. Bauer, A. E., Maegbaek, M. L., Liu, X., et al. (2018). Familiality of psychiatric disorders and risk of postpartum psychiatric episodes: A population-based cohort study. The American Journal of Psychiatry, 175(8), 783-791. https://doi.org/10.1176/appi.ajp.2018.17111184
  7. Bergink, V., Akbarian, S., Byatt, N., et al. (2026). Postpartum psychosis and bipolar disorder: Review of neurobiology and expert consensus statement on classification. Biological Psychiatry, 99(9), 740-747. https://doi.org/10.1016/j.biopsych.2025.10.016
  8. Bergink, V., Armangue, T., Titulaer, M. J., et al. (2015a). Autoimmune encephalitis in postpartum psychosis. The American Journal of Psychiatry, 172(9), 901-908. https://doi.org/10.1176/appi.ajp.2015.14101332
  9. Bergink, V., Bouvy, P. F., Vervoort, J. S., et al. (2012). Prevention of postpartum psychosis and mania in women at high risk. The American Journal of Psychiatry, 169(6), 609-615. https://doi.org/10.1176/appi.ajp.2012.11071047
  10. Bergink, V., Burgerhout, K. M., Koorengevel, K. M., et al. (2015b). Treatment of psychosis and mania in the postpartum period. The American Journal of Psychiatry, 172(2), 115-123. https://doi.org/10.1176/appi.ajp.2014.13121652
  11. Bergink, V., Burgerhout, K. M., Weigelt, K., et al. (2013). Immune system dysregulation in first-onset postpartum psychosis. Biological Psychiatry, 73(10), 1000-1007. https://doi.org/10.1016/j.biopsych.2012.11.006
  12. Bergink, V., Kushner, S. A., Pop, V., et al. (2011). Prevalence of autoimmune thyroid dysfunction in postpartum psychosis. The British Journal of Psychiatry, 198(4), 264-268. https://doi.org/10.1192/bjp.bp.110.082990
  13. Bergink, V., Pop, V. J. M., Nielsen, P. R., et al. (2018). Comorbidity of autoimmune thyroid disorders and psychiatric disorders during the postpartum period: A Danish nationwide register-based cohort study. Psychological Medicine, 48(8), 1291-1298. https://doi.org/10.1017/S0033291717002732
  14. Bergink, V., Rasgon, N., & Wisner, K. L. (2016). Postpartum psychosis: Madness, mania, and melancholia in motherhood. The American Journal of Psychiatry, 173(12), 1179-1188. https://doi.org/10.1176/appi.ajp.2016.16040454
  15. Bergink, V., Suleiman, M., Hennen, M. A., & Robakis, T. (2025). Management of bipolar disorder in pregnancy and postpartum: A clinicians' guide. CNS Drugs, 39(8), 763-777. https://doi.org/10.1007/s40263-025-01202-7
  16. Betcher, H. K., Vydysh, A., Ellington, B. D., & Clark, C. T. (2026). Management of lithium in pregnancy and lactation: An individualized approach. Current Psychiatry Reports, 28(1), 32. https://doi.org/10.1007/s11920-026-01674-4
  17. Brockington, I. (2004). Postpartum psychiatric disorders. Lancet, 363(9405), 303-310. https://doi.org/10.1016/S0140-6736(03)15390-1
  18. Brockington, I. (2017a). Some unusual forms of early onset postpartum psychosis. Archives of Women's Mental Health, 20(1), 71-76. https://doi.org/10.1007/s00737-016-0676-7
  19. Brockington, I. (2017b). Suicide and filicide in postpartum psychosis. Archives of Women's Mental Health, 20(1), 63-69. https://doi.org/10.1007/s00737-016-0675-8
  20. Burgerhout, K. M., Kamperman, A. M., Roza, S. J., et al. (2017). Functional recovery after postpartum psychosis: A prospective longitudinal study. The Journal of Clinical Psychiatry, 78(1), 122-128. https://doi.org/10.4088/JCP.15m10204
  21. Carlson, J., & Kulkarni, J. (2026). Estradiol surges as dual-purpose mechanisms in evolutionary psychiatry. Neuroscience and Biobehavioral Reviews, 187, 106760. https://doi.org/10.1016/j.neubiorev.2026.106760
  22. Carr, C., Borges, D., Lewis, K., et al. (2023). Sleep and postpartum psychosis: A narrative review of the existing literature. Journal of Clinical Medicine, 12(24), 7550. https://doi.org/10.3390/jcm12247550
  23. Cohen, L. S., Arakelian, M., Church, T. R., et al. (2025). The phenomenology of postpartum psychosis: Preliminary findings from the Massachusetts General Hospital postpartum psychosis project. Molecular Psychiatry, 30(6), 2537-2544. https://doi.org/10.1038/s41380-024-02856-3
  24. Davies, W. (2026). Does hypothalamic CCN3 hypersecretion confer postpartum mood disorder risk? Translational Psychiatry, 16(1), 195. https://doi.org/10.1038/s41398-026-03969-9
  25. Dazzan, P., Fusté, M., & Davies, W. (2018). Do defective immune system-mediated myelination processes increase postpartum psychosis risk? Trends in Molecular Medicine, 24(11), 942-949. https://doi.org/10.1016/j.molmed.2018.09.002
  26. Degremont, A., Kerbrat, S., Balusson, F., et al. (2022). Prescribing trends for valproate among pregnant women. Neurology, 98(21), e2163-e2173. https://doi.org/10.1212/WNL.0000000000200260
  27. Di Florio, A., Forty, L., Gordon-Smith, K., et al. (2013). Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry, 70(2), 168-175. https://doi.org/10.1001/jamapsychiatry.2013.279
  28. Di Florio, A., Mei Kay Yang, J., Crawford, K., et al. (2021). Post-partum psychosis and its association with bipolar disorder in the UK. The Lancet Psychiatry, 8(12), 1045-1052. https://doi.org/10.1016/S2215-0366(21)00253-4
  29. Essali, A., Alabed, S., Guul, A., & Essali, N. (2013). Preventive interventions for postnatal psychosis. Cochrane Database of Systematic Reviews, (6), CD009991. https://doi.org/10.1002/14651858.CD009991.pub2
  30. Fornaro, M., Maritan, E., Ferranti, R., et al. (2020). Lithium exposure during pregnancy and the postpartum period: A systematic review and meta-analysis. The American Journal of Psychiatry, 177(1), 76-92. https://doi.org/10.1176/appi.ajp.2019.19030228
  31. Gilden, J., Kamperman, A. M., Munk-Olsen, T., et al. (2020). Long-term outcomes of postpartum psychosis: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 81(2), 19r12906. https://doi.org/10.4088/JCP.19r12906
  32. Gilden, J., Poels, E. M. P., Lambrichts, S., et al. (2021). Bipolar episodes after reproductive events in women with bipolar I disorder, a study of 919 pregnancies. Journal of Affective Disorders, 295, 72-79. https://doi.org/10.1016/j.jad.2021.08.006
  33. Hedges, V. L., Heaton, E. C., Amaral, C., et al. (2021). Estrogen withdrawal increases postpartum anxiety via oxytocin plasticity. Biological Psychiatry, 89(9), 929-938. https://doi.org/10.1016/j.biopsych.2020.11.016
  34. Hernandez-Diaz, S., Quinn, M., Conant, S., et al. (2025). Use of antiseizure medications early in pregnancy and the risk of major malformations in the newborn. Neurology, 105(3), e213786. https://doi.org/10.1212/WNL.0000000000213786
  35. Herrera-Barrón, O., Cors-Cepeda, X., López-García, C., et al. (2026). Effectiveness of electroconvulsive therapy in postpartum psychosis: A systematic review. The Journal of ECT, 42(2), 86-95. https://doi.org/10.1097/YCT.0000000000001188
  36. Howard, L. M., Trevillion, K., Potts, L., et al. (2022). Effectiveness and cost-effectiveness of psychiatric mother and baby units. The British Journal of Psychiatry, 221(4), 628-636. https://doi.org/10.1192/bjp.2022.48
  37. İlhan, R. S., Can, K. C., Şahiner, Ş. Y., et al. (2025). Hashimoto's encephalopathy in psychiatric inpatients. Frontiers in Psychiatry, 16, 1639179. https://doi.org/10.3389/fpsyt.2025.1639179
  38. Imaz, M. L., Soy, D., Torra, M., et al. (2021). Clinical and pharmacokinetic profile of lithium monotherapy in exclusive breastfeeding. Frontiers in Pharmacology, 12, 647414. https://doi.org/10.3389/fphar.2021.647414
  39. Imaz, M. L., Torra, M., Soy, D., García-Esteve, L., & Martin-Santos, R. (2019). Clinical lactation studies of lithium: A systematic review. Frontiers in Pharmacology, 10, 1005. https://doi.org/10.3389/fphar.2019.01005
  40. Jeste, D. V., Lieberman, J. A., Fassler, D., et al. (2022). Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association.
  41. Jones, I., Hamshere, M., Nangle, J. M., et al. (2007). Bipolar affective puerperal psychosis: Genome-wide significant evidence for linkage to chromosome 16. The American Journal of Psychiatry, 164(7), 1099-1104. https://doi.org/10.1176/appi.ajp.2007.164.7.1099
  42. Jung, S., Caballero, M., Kępińska, A., et al. (2026). Genetic architecture of postpartum psychosis: From common to rare genetic variation. Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03637-w
  43. Kamperman, A. M., Veldman-Hoek, M. J., Wesseloo, R., Robertson Blackmore, E., & Bergink, V. (2017). Phenotypical characteristics of postpartum psychosis. Bipolar Disorders, 19(6), 450-457. https://doi.org/10.1111/bdi.12523
  44. Kępińska, A. P., Robakis, T. K., Humphreys, K., et al. (2025). Familial risk of postpartum psychosis. The American Journal of Psychiatry, 182(6), 542-550. https://doi.org/10.1176/appi.ajp.20230576
  45. Meltzer-Brody, S., Howard, L. M., Bergink, V., et al. (2018). Postpartum psychiatric disorders. Nature Reviews Disease Primers, 4, 18022. https://doi.org/10.1038/nrdp.2018.22
  46. Michalczyk, J., Miłosz, A., & Soroka, E. (2023). Postpartum psychosis: A review of risk factors, clinical picture, management, prevention, and psychosocial determinants. Medical Science Monitor, 29, e942520. https://doi.org/10.12659/MSM.942520
  47. Munk-Olsen, T., Ingstrup, K. G., Johannsen, B. M., & Liu, X. (2020). Population-based assessment of the recurrence risk of postpartum mental disorders. JAMA Psychiatry, 77(2), 213-214. https://doi.org/10.1001/jamapsychiatry.2019.3208
  48. Munk-Olsen, T., Laursen, T. M., Meltzer-Brody, S., Mortensen, P. B., & Jones, I. (2012). Psychiatric disorders with postpartum onset: Possible early manifestations of bipolar affective disorders. Archives of General Psychiatry, 69(4), 428-434. https://doi.org/10.1001/archgenpsychiatry.2011.157
  49. Nahar, A., Kondapuram, N., Desai, G., & Chandra, P. S. (2017). Catatonia among women with postpartum psychosis in a mother-baby inpatient psychiatry unit. General Hospital Psychiatry, 45, 40-43. https://doi.org/10.1016/j.genhosppsych.2016.12.010
  50. Osborne, L. M. (2018). Recognizing and managing postpartum psychosis: A clinical guide for obstetric providers. Obstetrics and Gynecology Clinics of North America, 45(3), 455-468. https://doi.org/10.1016/j.ogc.2018.04.005
  51. Pacchiarotti, I., León-Caballero, J., Murru, A., et al. (2016). Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. European Neuropsychopharmacology, 26(10), 1562-1578. https://doi.org/10.1016/j.euroneuro.2016.08.008
  52. Perry, A., Gordon-Smith, K., Di Florio, A., et al. (2021). Mood episodes in pregnancy and risk of postpartum recurrence in bipolar disorder. Journal of Affective Disorders, 294, 714-722. https://doi.org/10.1016/j.jad.2021.07.067
  53. Perry, A., Gordon-Smith, K., Lewis, K. J. S., et al. (2024). Perinatal sleep disruption and postpartum psychosis in bipolar disorder. Journal of Affective Disorders, 346, 21-27. https://doi.org/10.1016/j.jad.2023.11.005
  54. Reddy, M. S. S., Thippeswamy, H., Ganjekar, S., et al. (2018). Anti-NMDA receptor encephalitis presenting as postpartum psychosis. Archives of Women's Mental Health, 21(4), 465-469. https://doi.org/10.1007/s00737-018-0816-3
  55. Robertson, E., Jones, I., Haque, S., Holder, R., & Craddock, N. (2005). Risk of puerperal and non-puerperal recurrence of illness following bipolar affective puerperal (post-partum) psychosis. The British Journal of Psychiatry, 186, 258-259. https://doi.org/10.1192/bjp.186.3.258
  56. Rundgren, S., Brus, O., Båve, U., et al. (2018). Improvement of postpartum depression and psychosis after electroconvulsive therapy. Journal of Affective Disorders, 235, 258-264. https://doi.org/10.1016/j.jad.2018.04.043
  57. Schoretsanitis, G., Westin, A. A., Deligiannidis, K. M., Spigset, O., & Paulzen, M. (2020). Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk. Therapeutic Drug Monitoring, 42(2), 245-254. https://doi.org/10.1097/FTD.0000000000000692
  58. Sharma, V., Doobay, M., & Baczynski, C. (2017). Bipolar postpartum depression: An update and recommendations. Journal of Affective Disorders, 219, 105-111. https://doi.org/10.1016/j.jad.2017.05.014
  59. Sharma, V., & Mazmanian, D. (2014). The DSM-5 peripartum specifier: Prospects and pitfalls. Archives of Women's Mental Health, 17(2), 171-173. https://doi.org/10.1007/s00737-013-0406-3
  60. Song, B., Yuan, Y., Li, Z., et al. (2026). Postpartum delirious mania in a patient with diagnosis of bipolar disorder after cesarean delivery. Frontiers in Psychiatry, 17, 1821115. https://doi.org/10.3389/fpsyt.2026.1821115
  61. Spinelli, M. (2021). Postpartum psychosis: A diagnosis for the DSMV. Archives of Women's Mental Health, 24(5), 817-822. https://doi.org/10.1007/s00737-021-01175-8
  62. Stewart, D. E., & Vigod, S. (2016). Postpartum depression. The New England Journal of Medicine, 375(22), 2177-2186. https://doi.org/10.1056/NEJMcp1607649
  63. Teodorescu, A., Dima, L., Popa, M. A., et al. (2020). Antipsychotics in postpartum psychosis. American Journal of Therapeutics, 28(3), e341-e348. https://doi.org/10.1097/MJT.0000000000001218
  64. Tsokkou, S., Kavvadas, D., Georgaki, M. N., et al. (2024). Genetic and epigenetic factors associated with postpartum psychosis: A 5-year systematic review. Journal of Clinical Medicine, 13(4), 964. https://doi.org/10.3390/jcm13040964
  65. Uguz, F. (2016). Second-generation antipsychotics during the lactation period. Journal of Clinical Psychopharmacology, 36(3), 244-252. https://doi.org/10.1097/JCP.0000000000000491
  66. Valdimarsdóttir, U., Hultman, C. M., Harlow, B., Cnattingius, S., & Sparén, P. (2009). Psychotic illness in first-time mothers with no previous psychiatric hospitalizations. PLoS Medicine, 6(2), e13. https://doi.org/10.1371/journal.pmed.1000013
  67. VanderKruik, R., Barreix, M., Chou, D., et al. (2017). The global prevalence of postpartum psychosis: A systematic review. BMC Psychiatry, 17(1), 272. https://doi.org/10.1186/s12888-017-1427-7
  68. Viguera, A. C., Newport, D. J., Ritchie, J., et al. (2007). Lithium in breast milk and nursing infants: Clinical implications. The American Journal of Psychiatry, 164(2), 342-345. https://doi.org/10.1176/ajp.2007.164.2.342
  69. Wesseloo, R., Kamperman, A. M., Munk-Olsen, T., et al. (2016). Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. The American Journal of Psychiatry, 173(2), 117-127. https://doi.org/10.1176/appi.ajp.2015.15010124
  70. Wilson, J. E., Oldham, M. A., Francis, A., et al. (2025). Resource Document on Catatonia. American Psychiatric Association.
  71. Wisner, K. L., Murphy, C., & Thomas, M. M. (2024). Prioritizing maternal mental health in addressing morbidity and mortality. JAMA Psychiatry, 81(5), 521-526. https://doi.org/10.1001/jamapsychiatry.2023.5648
  72. Zhou, J. Y., Xu, B., Lopes, J., Blamoun, J., & Li, L. (2017). Hashimoto encephalopathy: Literature review. Acta Neurologica Scandinavica, 135(3), 285-290. https://doi.org/10.1111/ane.12618

Down Syndrome, Psychosis and Regression

Read the article →
  1. Anand, V., Shukla, G., Gupta, N., et al. (2021). Association of sleep apnea with development and behavior in Down syndrome: A prospective clinical and polysomnographic study. Pediatric Neurology, 116, 7-13. https://doi.org/10.1016/j.pediatrneurol.2020.10.007
  2. Appiani, F. J., Duarte, J. M., Sauré, M., et al. (2023). Catatonia and delirium: Assessment of comorbidity, prevalence, and therapeutic response in medically ill inpatients from a university hospital. Journal of Clinical Psychopharmacology, 43(1), 55-59. https://doi.org/10.1097/JCP.0000000000001621
  3. Araya, P., Waugh, K. A., Sullivan, K. D., et al. (2019). Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proceedings of the National Academy of Sciences of the United States of America, 116(48), 24231-24241. https://doi.org/10.1073/pnas.1908129116
  4. Arranz, J., Lantero-Rodríguez, J., Braun-Wohlfahrt, L. S., et al. (2026). CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum. EBioMedicine, 130, 106370. https://doi.org/10.1016/j.ebiom.2026.106370
  5. Ayub, M., Saeed, K., Munshi, T. A., & Naeem, F. (2015). Clozapine for psychotic disorders in adults with intellectual disabilities. The Cochrane Database of Systematic Reviews, (9), CD010625. https://doi.org/10.1002/14651858.CD010625.pub2
  6. Baksh, R. A., Pape, S. E., Chan, L. F., et al. (2023). Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: A population-based cohort study using electronic health records. The Lancet Public Health, 8(6), e453-e462. https://doi.org/10.1016/S2468-2667(23)00057-9
  7. Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016). Dementia in Down's syndrome. The Lancet Neurology, 15(6), 622-636. https://doi.org/10.1016/S1474-4422(16)00063-6
  8. Barišić, A., Ravančić, M. E., Majstorivić, D., & Vraneković, J. (2023). Micronutrient status in children and adolescents with Down syndrome: Systematic review and meta-analysis. Journal of Intellectual Disability Research: JIDR, 67(8), 701-719. https://doi.org/10.1111/jir.13042
  9. Beresford-Webb, J. A., Mak, E., Grigorova, M., et al. (2021). Establishing diagnostic thresholds for Alzheimer's disease in adults with Down syndrome: The Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities (CAMDEX-DS). BJPsych Open, 7(3), e79. https://doi.org/10.1192/bjo.2021.36
  10. Betoni, N. J., Okamoto, C. M., Lott, I. T., & Hom, C. L. (2025). Cognitive and behavioural associations of visual and hearing impairments across the lifespan in people with Down syndrome, a scoping review. Journal of Intellectual Disability Research: JIDR. https://doi.org/10.1111/jir.13248
  11. Boelen, R., & de Vries, T. (2021). Clinical characteristics of paediatric Hashimoto's encephalopathy. European Journal of Paediatric Neurology, 32, 122-127. https://doi.org/10.1016/j.ejpn.2021.04.006
  12. Bonne, S., Iftimovici, A., Mircher, C., et al. (2023). Down syndrome regression disorder, a case series: Clinical characterization and therapeutic approaches. Frontiers in Neuroscience, 17, 1126973. https://doi.org/10.3389/fnins.2023.1126973
  13. Brodtmann, A. (2009). Hashimoto encephalopathy and Down syndrome. Archives of Neurology, 66(5), 663-666. https://doi.org/10.1001/archneurol.2009.45
  14. Bull, M. J. (2020). Down syndrome. The New England Journal of Medicine, 382(24), 2344-2352. https://doi.org/10.1056/NEJMra1706537
  15. Bull, M. J., Trotter, T., Santoro, S. L., et al. (2022). Health supervision for children and adolescents with Down syndrome. Pediatrics, 149(5), e2022057010. https://doi.org/10.1542/peds.2022-057010
  16. Capone, G. T., Goyal, P., Grados, M., Smith, B., & Kammann, H. (2008). Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study. Journal of Developmental and Behavioral Pediatrics: JDBP, 29(2), 106-116. https://doi.org/10.1097/DBP.0b013e318165c100
  17. Charlot, L. R., Doerfler, L. A., & McLaren, J. L. (2020). Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities. Journal of Intellectual Disability Research: JIDR, 64(11), 852-863. https://doi.org/10.1111/jir.12777
  18. Ciciora, S. L., Manickam, K., & Saps, M. (2023). Disorders of gut-brain interaction in a national cohort of children with Down syndrome. Journal of Neurogastroenterology and Motility, 29(1), 94-101. https://doi.org/10.5056/jnm22055
  19. Collacott, R. A., Cooper, S. A., & McGrother, C. (1992). Differential rates of psychiatric disorders in adults with Down's syndrome compared with other mentally handicapped adults. The British Journal of Psychiatry: The Journal of Mental Science, 161, 671-674. https://doi.org/10.1192/bjp.161.5.671
  20. Connors, M. H., Sachdev, P. S., Colebatch, J. G., et al. (2024). Case report: Down syndrome regression disorder, catatonia, and psychiatric and immunomodulatory interventions. Frontiers in Psychiatry, 15, 1416736. https://doi.org/10.3389/fpsyt.2024.1416736
  21. Cooper, S. A., Melville, C. A., & Einfeld, S. L. (2003). Psychiatric diagnosis, intellectual disabilities and diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC-LD). Journal of Intellectual Disability Research: JIDR, 47(S1), 3-15. https://doi.org/10.1046/j.1365-2788.47.s1.2.x
  22. Corniello, C., Dono, F., Evangelista, G., et al. (2024). Diagnosis and treatment of status epilepticus in Down syndrome (DS): A case report and systematic literature review. Seizure, 114, 90-95. https://doi.org/10.1016/j.seizure.2023.11.009
  23. Deb, S., Hare, M., Prior, L., & Bhaumik, S. (2007). Dementia screening questionnaire for individuals with intellectual disabilities. The British Journal of Psychiatry: The Journal of Mental Science, 190, 440-444. https://doi.org/10.1192/bjp.bp.106.024984
  24. Deutsch, S. I., & Burket, J. A. (2021). Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 104, 110017. https://doi.org/10.1016/j.pnpbp.2020.110017
  25. Einfeld, S. L., Piccinin, A. M., Mackinnon, A., et al. (2006). Psychopathology in young people with intellectual disability. JAMA, 296(16), 1981-1989. https://doi.org/10.1001/jama.296.16.1981
  26. Espinoza, R. T., & Kellner, C. H. (2022). Electroconvulsive therapy. The New England Journal of Medicine, 386(7), 667-672. https://doi.org/10.1056/NEJMra2034954
  27. Ferriero, D. M., Fullerton, H. J., Bernard, T. J., et al. (2019). Management of stroke in neonates and children: A scientific statement from the American Heart Association/American Stroke Association. Stroke, 50(3), e51-e96. https://doi.org/10.1161/STR.0000000000000183
  28. Food and Drug Administration. FDA Orange Book.
  29. Forte, L., Bianco, A., & Bertelli, M. O. (2026). Instrumental assessment of psychotic disorders in intellectual developmental disorders and autism with cognitive or major communication issues. Current Opinion in Psychiatry, 39(2), 83-90. https://doi.org/10.1097/YCO.0000000000001075
  30. Fortea, J., Vilaplana, E., Carmona-Iragui, M., et al. (2020). Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. The Lancet, 395(10242), 1988-1997. https://doi.org/10.1016/S0140-6736(20)30689-9
  31. Fortea, J., Zaman, S. H., Hartley, S., et al. (2021). Alzheimer's disease associated with Down syndrome: A genetic form of dementia. The Lancet Neurology, 20(11), 930-942. https://doi.org/10.1016/S1474-4422(21)00245-3
  32. Fotheringham, J. B., & Thompson, F. (1994). Case report of a person with Down's syndrome and multiple personality disorder. Canadian Journal of Psychiatry, 39(2), 116-119. https://doi.org/10.1177/070674379403900210
  33. Ghaziuddin, N., Nassiri, A., & Miles, J. H. (2015). Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatric Disease and Treatment, 11, 941-949. https://doi.org/10.2147/NDT.S77307
  34. Glasson, E. J., Buckley, N., Chen, W., et al. (2020). Systematic review and meta-analysis: Mental health in children with neurogenetic disorders associated with intellectual disability. Journal of the American Academy of Child and Adolescent Psychiatry, 59(9), 1036-1048. https://doi.org/10.1016/j.jaac.2020.01.006
  35. Grotteschi, N., Rochat, M. J., Pollarini, V., et al. (2025). Neurological findings in a cohort of adults with Down syndrome. Neurological Sciences. https://doi.org/10.1007/s10072-025-08195-7
  36. Hamad, A. P., Ferrari-Marinho, T., Caboclo, L. O., Thomé, U., & Fernandes, R. M. F. (2020). Nonconvulsive status epilepticus in epileptic encephalopathies in childhood. Seizure, 80, 212-220. https://doi.org/10.1016/j.seizure.2020.06.024
  37. Hart, S. J., Worley, G., Kishnani, P. S., & Van Mater, H. (2021). Case report: Improvement following immunotherapy in an individual with seronegative Down syndrome disintegrative disorder. Frontiers in Neurology, 12, 621637. https://doi.org/10.3389/fneur.2021.621637
  38. Hasan, S., Desarkar, P., Lunsky, Y., & Thakur, A. (2025). Catatonia in autistic adults in a tertiary inpatient and outpatient neurodevelopmental service: A retrospective review. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-025-06837-5
  39. Heckers, S., & Walther, S. (2023). Catatonia. The New England Journal of Medicine, 389(19), 1797-1802. https://doi.org/10.1056/NEJMra2116304
  40. Hua, L. L. (2021). Collaborative care in the identification and management of psychosis in adolescents and young adults. Pediatrics, 147(6), e2021051486. https://doi.org/10.1542/peds.2021-051486
  41. Huber, H., Arranz, J., Arslan, B., et al. (2025). Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome. Nature Communications, 16(1), 9900. https://doi.org/10.1038/s41467-025-65882-x
  42. Jafarpour, S., Banerjee, A. K., Khoshnood, M. M., et al. (2024). De novo variants in immune regulatory genes in Down syndrome regression disorder. Journal of Neurology, 271(8), 5567-5576. https://doi.org/10.1007/s00415-024-12521-y
  43. Janelidze, S., Collij, L. E., Mattsson-Carlgren, N., et al. (2025). Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: A longitudinal cohort study. The Lancet Neurology, 24(7), 591-600. https://doi.org/10.1016/S1474-4422(25)00158-9
  44. Kainth, D. S., Chaudhry, S. A., Kainth, H. S., Suri, F. K., & Qureshi, A. I. (2013). Prevalence and characteristics of concurrent Down syndrome in patients with moyamoya disease. Neurosurgery, 72(2), 210-215. https://doi.org/10.1227/NEU.0b013e31827b9beb
  45. Kaur, S., Silver, G., Samuels, S., et al. (2020). Delirium and developmental disability: Improving specificity of a pediatric delirium screen. Pediatric Critical Care Medicine, 21(5), 409-414. https://doi.org/10.1097/PCC.0000000000002248
  46. Kelley, B. J., Bailey, K. J., & Hubregsen, J. J. (2025). Clinical response to electroconvulsive therapy in a young adult with Down syndrome regression disorder. The Journal of ECT, 41(2), e18-e20. https://doi.org/10.1097/YCT.0000000000001093
  47. Komatsu, H., Nishimura, A., Okano, S., et al. (1992). Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification. Brain & Development, 14(6), 400-403. https://doi.org/10.1016/s0387-7604(12)80348-2
  48. Kong, X. F., Worley, L., Rinchai, D., et al. (2020). Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. Journal of Clinical Immunology, 40(6), 807-819. https://doi.org/10.1007/s10875-020-00803-9
  49. Lautarescu, B. A., Holland, A. J., & Zaman, S. H. (2017). The early presentation of dementia in people with Down syndrome: A systematic review of longitudinal studies. Neuropsychology Review, 27(1), 31-45. https://doi.org/10.1007/s11065-017-9341-9
  50. Lichtor, S. A., Berk, R., Gimler, K., & Siegel, M. (2026). Communicating constipation: Differential diagnosis of agitation in autism at a pediatric hospital. Pediatrics, 157(5), e2025073672. https://doi.org/10.1542/peds.2025-073672
  51. Liu, E., Wolter-Warmerdam, K., Marmolejo, J., et al. (2020). Routine screening for celiac disease in children with Down syndrome improves case finding. Journal of Pediatric Gastroenterology and Nutrition, 71(2), 252-256. https://doi.org/10.1097/MPG.0000000000002742
  52. Malle, L., Patel, R. S., Martin-Fernandez, M., et al. (2023). Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells. Nature, 615(7951), 305-314. https://doi.org/10.1038/s41586-023-05736-y
  53. Mannion, A., Neil, N., Fiani, T., et al. (2024). An investigation of sleep problems, gastrointestinal symptoms, comorbid psychopathology and challenging behavior in children and adolescents with Down syndrome. Research in Developmental Disabilities, 151, 104788. https://doi.org/10.1016/j.ridd.2024.104788
  54. Mantry, D., Cooper, S. A., Smiley, E., et al. (2008). The prevalence and incidence of mental ill-health in adults with Down syndrome. Journal of Intellectual Disability Research: JIDR, 52(2), 141-155. https://doi.org/10.1111/j.1365-2788.2007.00985.x
  55. Matsui Yamaguchi, M. Y., Silva Nunes, C. N., de Freitas Júnior, W. R., et al. (2026). Prevalence and severity of sleep-disordered breathing in individuals with Down syndrome using a portable home-based diagnostic device: A pilot study. Scientific Reports, 16(1), 22905. https://doi.org/10.1038/s41598-026-46328-w
  56. Melville, C. A. (2003). A critique of the diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC-LD) chapter on non-affective psychotic disorders. Journal of Intellectual Disability Research: JIDR, 47(S1), 16-25. https://doi.org/10.1046/j.1365-2788.47.s1.12.x
  57. Miles, J. H., Takahashi, N., Muckerman, J., Nowell, K. P., & Ithman, M. (2019). Catatonia in Down syndrome: Systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatric Disease and Treatment, 15, 2723-2741. https://doi.org/10.2147/NDT.S210613
  58. Minamisawa, Y., Sato, M., Saito, Y., et al. (2023). Case report: Evolution of catatonic mutism and psychotic symptoms in an adolescent with Down syndrome: Transition from Down syndrome disintegrative disorder to anti-N-methyl-D-aspartate receptor encephalitis. Frontiers in Neurology, 14, 1200541. https://doi.org/10.3389/fneur.2023.1200541
  59. Morgan, V. A., Leonard, H., Bourke, J., & Jablensky, A. (2008). Intellectual disability co-occurring with schizophrenia and other psychiatric illness: Population-based study. The British Journal of Psychiatry: The Journal of Mental Science, 193(5), 364-372. https://doi.org/10.1192/bjp.bp.107.044461
  60. Moss, S., Prosser, H., & Goldberg, D. (1996). Validity of the schizophrenia diagnosis of the Psychiatric Assessment Schedule for Adults with Developmental Disability (PAS-ADD). The British Journal of Psychiatry: The Journal of Mental Science, 168(3), 359-367. https://doi.org/10.1192/bjp.168.3.359
  61. Musaeus, C. S., Salem, L. C., Sabers, A., Kjaer, T. W., & Waldemar, G. (2019). Associations between electroencephalography power and Alzheimer's disease in persons with Down syndrome. Journal of Intellectual Disability Research: JIDR, 63(9), 1151-1157. https://doi.org/10.1111/jir.12627
  62. Nordstrøm, M., Retterstøl, K., Hope, S., & Kolset, S. O. (2020). Nutritional challenges in children and adolescents with Down syndrome. The Lancet Child & Adolescent Health, 4(6), 455-464. https://doi.org/10.1016/S2352-4642(19)30400-6
  63. Ortega, M. D. C., Ortuño, F., & Real de Asúa, D. (2026). Psychosocial stressors prior to Down syndrome regression disorder: Findings from two referral clinics. Frontiers in Psychiatry, 17, 1799799. https://doi.org/10.3389/fpsyt.2026.1799799
  64. Palumbo, M. L., & McDougle, C. J. (2018). Pharmacotherapy of Down syndrome. Expert Opinion on Pharmacotherapy, 19(17), 1875-1889. https://doi.org/10.1080/14656566.2018.1529167
  65. Patel, H., & McGuirk, R. (2025). Vitamin B12 deficiency: Common questions and answers. American Family Physician, 112(3), 294-300.
  66. Prout, K. K., Kitchen, J., Tobler, L., & Nyp, S. S. (2025). Self-talk in a patient with Down syndrome: When is it a concern? Journal of Developmental and Behavioral Pediatrics: JDBP, 46(3), e326-e328. https://doi.org/10.1097/DBP.0000000000001359
  67. Rachubinski, A. L., Wallace, E., Gurnee, E., et al. (2024). JAK inhibition decreases the autoimmune burden in Down syndrome. eLife, 13, RP99323. https://doi.org/10.7554/eLife.99323
  68. Rafii, M. S., Schlachetzki, Z., Barroeta, I., et al. (2025). Down syndrome and Alzheimer's disease: Insights into biomarkers, clinical symptoms, and pathology. The Lancet Neurology, 24(9), 753-762. https://doi.org/10.1016/S1474-4422(25)00237-6
  69. Ray, W. A., Fuchs, D. C., Olfson, M., et al. (2024). Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth: A national cohort study. Journal of Child and Adolescent Psychopharmacology, 34(9), 397-406. https://doi.org/10.1089/cap.2024.0047
  70. Rodriguez, L., Ambartsumyan, L., Baumgartner, K., et al. (2026). American Gastroenterological Association-North American Society for Pediatric Gastroenterology, Hepatology and Nutrition pediatric functional constipation clinical care pathway. Clinical Gastroenterology and Hepatology, S1542-3565(26)00159-X. https://doi.org/10.1016/j.cgh.2026.03.003
  71. Roizen, N. J., & Patterson, D. (2003). Down's syndrome. The Lancet, 361(9365), 1281-1289. https://doi.org/10.1016/S0140-6736(03)12987-X
  72. Rosso, M., Fremion, E., Santoro, S. L., et al. (2020). Down syndrome disintegrative disorder: A clinical regression syndrome of increasing importance. Pediatrics, 145(6), e20192939. https://doi.org/10.1542/peds.2019-2939
  73. Sahu, P., Thippeswamy, H., & Chaturvedi, S. K. (2022). Neuropsychiatric manifestations in vitamin B12 deficiency. Vitamins and Hormones, 119, 457-470. https://doi.org/10.1016/bs.vh.2022.01.001
  74. Samsel, C., Brahmbhatt, K., Smith, J. R., et al. (2026). Recommendations for a pediatric catatonia clinical pathway in acute medical care settings: A Delphi consensus study. Journal of the Academy of Consultation-Liaison Psychiatry. https://doi.org/10.1016/j.jaclp.2026.03.007
  75. Santoro, J. D., Filipink, R. A., Baumer, N. T., Bulova, P. D., & Handen, B. L. (2023). Down syndrome regression disorder: Updates and therapeutic advances. Current Opinion in Psychiatry, 36(2), 96-103. https://doi.org/10.1097/YCO.0000000000000845
  76. Santoro, J. D., Jafarpour, S., Keehan, L., et al. (2024). Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder. Scientific Reports, 14(1), 30865. https://doi.org/10.1038/s41598-024-81819-8
  77. Santoro, J. D., Khoshnood, M. M., Nguyen, L., et al. (2025). Alternative diagnoses in the work up of Down syndrome regression disorder. Journal of Autism and Developmental Disorders, 55(6), 2085-2091. https://doi.org/10.1007/s10803-023-06057-9
  78. Santoro, J. D., Lee, S., Mlynash, M., et al. (2018). Blood pressure elevation and risk of moyamoya syndrome in patients with trisomy 21. Pediatrics, 142(4), e20180840. https://doi.org/10.1542/peds.2018-0840
  79. Santoro, J. D., Nguyen, L., Nishimori, N. A., et al. (2025). Safety and tolerability of home infusions in Down syndrome regression disorder. Clinical Therapeutics, 47(2), e27-e33. https://doi.org/10.1016/j.clinthera.2024.11.023
  80. Santoro, J. D., Patel, L., Kammeyer, R., et al. (2022). Assessment and diagnosis of Down syndrome regression disorder: International expert consensus. Frontiers in Neurology, 13, 940175. https://doi.org/10.3389/fneur.2022.940175
  81. Santoro, J. D., Silverman, M., Kazerooni, L., et al. (2026). Serum and cerebral folate are normal in Down syndrome regression disorder. Molecular Autism, 17(1), 9. https://doi.org/10.1186/s13229-026-00703-6
  82. Santoro, J. D., Silverman, M., Wang, A. C., et al. (2026). Delayed recognition and stroke-predominant presentation in Down syndrome-associated moyamoya syndrome. Stroke. https://doi.org/10.1161/STROKEAHA.126.056969
  83. Santoro, J. D., Spinazzi, N. A., Filipink, R. A., et al. (2023). Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Translational Psychiatry, 13(1), 276. https://doi.org/10.1038/s41398-023-02579-z
  84. Santoro, S. L., Cannon, S., Capone, G., et al. (2020). Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genetics in Medicine, 22(4), 767-776. https://doi.org/10.1038/s41436-019-0706-8
  85. Sargado, S., Milliken, A. L., Hojlo, M. A., et al. (2022). Is developmental regression in Down syndrome linked to life stressors? Journal of Developmental and Behavioral Pediatrics: JDBP, 43(7), 427-436. https://doi.org/10.1097/DBP.0000000000001086
  86. Seenivasan, A., Rachamim, E., & Santoro, J. D. (2025). A cross-sectional study survey to develop a clinical screen for Down syndrome regression disorder in the United Kingdom. American Journal of Medical Genetics Part A, e64207. https://doi.org/10.1002/ajmg.a.64207
  87. Sheehan, R., Horsfall, L., Strydom, A., et al. (2017). Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open, 7(8), e017406. https://doi.org/10.1136/bmjopen-2017-017406
  88. Shimizu, E., Goto-Hirano, K., Motoi, Y., Arai, M., & Hattori, N. (2024). Symptoms and age of prodromal Alzheimer's disease in Down syndrome: A systematic review and meta-analysis. Neurological Sciences, 45(6), 2445-2460. https://doi.org/10.1007/s10072-023-07292-9
  89. Shinomoto, M., Takeuchi, C., Tatebe, H., et al. (2024). Comparison between DSQIID total/sub-item scores and plasma p-tau elevation in adults with Down's syndrome. PLOS One, 19(12), e0311878. https://doi.org/10.1371/journal.pone.0311878
  90. Siegel, M., McGuire, K., Veenstra-VanderWeele, J., et al. (2020). Practice parameter for the assessment and treatment of psychiatric disorders in children and adolescents with intellectual disability (intellectual developmental disorder). Journal of the American Academy of Child and Adolescent Psychiatry, 59(4), 468-496. https://doi.org/10.1016/j.jaac.2019.11.018
  91. Silverman, W., Krinsky-McHale, S. J., Lai, F., et al. (2021). Evaluation of the National Task Group-Early Detection Screen for Dementia: Sensitivity to 'mild cognitive impairment' in adults with Down syndrome. Journal of Applied Research in Intellectual Disabilities: JARID, 34(3), 905-915. https://doi.org/10.1111/jar.12849
  92. Smith, J. R., Baldwin, I., Lim, S., & Luccarelli, J. (2024). Symptoms of catatonia observed in Down syndrome regressive disorder: A retrospective analysis. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-024-06249-x
  93. Smith, J. R., Hopkins, C. E., Xiong, J., et al. (2024). Use of ECT in autism spectrum disorder and/or intellectual disability: A single site retrospective analysis. Journal of Autism and Developmental Disorders, 54(3), 963-982. https://doi.org/10.1007/s10803-022-05868-6
  94. Sullivan, K. D., Evans, D., Pandey, A., et al. (2017). Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports, 7(1), 14818. https://doi.org/10.1038/s41598-017-13858-3
  95. Torr, J., & D'Abrera, J. C. (2014). Maintenance electroconvulsive therapy for depression with catatonia in a young woman with Down syndrome. The Journal of ECT, 30(4), 332-336. https://doi.org/10.1097/YCT.0000000000000116
  96. Totsika, V., Liew, A., Absoud, M., Adnams, C., & Emerson, E. (2022). Mental health problems in children with intellectual disability. The Lancet Child & Adolescent Health, 6(6), 432-444. https://doi.org/10.1016/S2352-4642(22)00067-0
  97. Tsou, A. Y., Bulova, P., Capone, G., et al. (2020). Medical care of adults with Down syndrome. JAMA, 324(15), 1543-1556. https://doi.org/10.1001/jama.2020.17024
  98. Ursumando, L., Fucà, E., Costanzo, F., & Vicari, S. (2022). Delusion of pregnancy in Down syndrome: Two case reports. International Journal of Environmental Research and Public Health, 19(20), 13339. https://doi.org/10.3390/ijerph192013339
  99. van Waarde, J. A., Stolker, J. J., & van der Mast, R. C. (2001). ECT in mental retardation: A review. The Journal of ECT, 17(4), 236-243. https://doi.org/10.1097/00124509-200112000-00002
  100. Walker, J. C., Dosen, A., Buitelaar, J. K., & Janzing, J. G. (2011). Depression in Down syndrome: A review of the literature. Research in Developmental Disabilities, 32(5), 1432-1440. https://doi.org/10.1016/j.ridd.2011.02.010
  101. Wang, S., Patel, L., Sannar, E. A., et al. (2023). Adverse childhood experiences and the development of Down syndrome regression disorder. American Journal of Medical Genetics Part A, 191(7), 1769-1782. https://doi.org/10.1002/ajmg.a.63199
  102. Waugh, K. A., Minter, R., Baxter, J., et al. (2023). Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nature Genetics, 55(6), 1034-1047. https://doi.org/10.1038/s41588-023-01399-7
  103. Wijdicks, E. F. M., & Ropper, A. H. (2024). Neuroleptic malignant syndrome. The New England Journal of Medicine, 391(12), 1130-1138. https://doi.org/10.1056/NEJMra2404606
  104. Wilson, J. E., Carlson, R., Duggan, M. C., et al. (2017). Delirium and catatonia in critically ill patients: The delirium and catatonia prospective cohort investigation. Critical Care Medicine, 45(11), 1837-1844. https://doi.org/10.1097/CCM.0000000000002642
  105. Wilson, J. E., Oldham, M. A., Francis, A., et al. (2025). Resource document on catatonia. American Psychiatric Association.
  106. Wisch, J. K., Jiao, Z., Kennedy, J. T., et al. (2026). Imaging and plasma biomarkers for pathological accumulation in Down syndrome. Brain: A Journal of Neurology, 149(6), 1944-1957. https://doi.org/10.1093/brain/awaf418
  107. Worley, G., Crissman, B. G., Cadogan, E., et al. (2015). Down syndrome disintegrative disorder: New-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. Journal of Child Neurology, 30(9), 1147-1152. https://doi.org/10.1177/0883073814554654
  108. Zalzal, H. G., & Lawlor, C. M. (2023). Down syndrome for the otolaryngologist. JAMA Otolaryngology--Head & Neck Surgery, 149(4), 360-367. https://doi.org/10.1001/jamaoto.2023.0001
  109. Zhou, J. Y., Xu, B., Lopes, J., Blamoun, J., & Li, L. (2017). Hashimoto encephalopathy: Literature review. Acta Neurologica Scandinavica, 135(3), 285-290. https://doi.org/10.1111/ane.12618